Figure 4. The effect of STX140 (20 mg/kg/daily p.o.) and paclitaxel (15 mg/kg/twice weekly i.v.) on tumor development in C3(1)/SV40 T-Ag mice.

A) Palpable tumors developed in all control and paclitaxel treated animals, but not in the STX140 treated group. B) When administered at 12 weeks of age (early intervention), STX140 inhibited development of the overall tumor burden throughout the study. C) and D) STX140, not paclitaxel, treatment (early intervention) gave a significant survival advantage to C3(1)/SV40 T-Ag mice. E) During the late intervention stage of the study, treatment with STX140 commenced when tumor burden was greater than 100 mm³. STX140 reduced tumor burden in these animals and F) conferred a significant survival advantage. Data represent mean ± s.e.m. * P<0.05, ** P<0.01, *** P<0.001 compared to controls. n = 10–15/group.